Aflibercept‑Ayyh Suppliers & Bulk Manufacturers
Available Forms: Intravitreal injection (liquid solution)
Available Strengths: 2 mg/0.05 mL
Reference Brands: Eylea(US & EU); Pavblu - biosimilar to biosimilar to Eylea
Category: Biosimilars
Pavblu, a biosimilar to Eylea (aflibercept), inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. It effectively treats age-related macular degeneration and diabetic retinopathy. Benefits include similar efficacy to Eylea, lower costs, and increased access to essential eye disease therapies. Aflibercept‑ayyh is available in Intravitreal injection (liquid solution) and strengths such as 2 mg/0.05 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Aflibercept‑ayyh is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Aflibercept‑ayyh can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Pavblu, a biosimilar of Eylea (aflibercept), is regulated in the EU and US with dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involves extensive comparability data, validation, and clinical validation. In the EU, CE marking certifies conformity under MDR standards. These biosimilars undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality ophthalmic biosimilars supporting effective treatment of eye diseases worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Aflibercept-ayyh is used to treat several serious eye conditions, including neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion. It works by inhibiting vascular endothelial growth factor (VEGF), thereby reducing abnormal blood vessel growth and leakage in the eye.
Aflibercept-ayyh is a recombinant fusion protein produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of portions of human VEGF receptors fused to the Fc portion of human IgG1, which binds VEGF-A and placental growth factor (PlGF).
The trade name of Aflibercept-ayyh is Eylea HD.
Aflibercept-ayyh (Eylea HD) is manufactured and marketed by Regeneron Pharmaceuticals, Inc., in collaboration with Bayer AG for certain global markets.
The generic name is Aflibercept-ayyh.
The brand name is Eylea HD.
Aflibercept-ayyh is manufactured by Regeneron Pharmaceuticals, Inc. at its biologics production facilities in Rensselaer, New York, USA.
Related Products
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Omalizumab‑Igec
Strength:
75 mg/0.5 mL and 150 mg/mL
Form: Pre filled syringe
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
View Details
Tocilizumab-Bavi
Strength:
80 mg/4ml
Form: Intravenous infusion
Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).
View DetailsQuick Response Guaranteed | Verified Suppliers
